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b Adjusted for: matching factors (child sex, month of birth, year of birth), parity, and maternal age, race/ethnicity, weight at sample collection, and birth place. Models in remaining columns of this table include these factors in addition to the additional covariate(s) listed in the column header.
c N for PC-adjusted analysis =781 (including 386 ASD cases and 395 GP controls), due to availability of genetic information. N for PCB and PBDE analyses=534 cases and 408 GP controls due to availability of organohalogen data on these congeners. 
